Carboplatin Alone Not Adequate for Ovarian Cancer in Frail Seniors
Worse survival than with combination carboplatin-paclitaxel regimens for vulnerable older patients with ovarian cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.